Research programme: PLR 14 - PLIVA d.d.Alternative Names: PLR 14 research programme - PLIVA d.d.
Latest Information Update: 16 Aug 2007
$50 / €47 *
At a glance
- Originator PLIVA d.d.
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Crohn's disease; Rheumatoid arthritis
Most Recent Events
- 15 Jul 2005 This programme is still in active development for Rheumatoid arthritis
- 15 Apr 2005 No development reported - Preclinical for Crohn's disease in Croatia (PO)
- 05 Jul 2002 Preclinical trials in Crohn's disease in Croatia (PO)